Form 4: 180 Life Sciences CEO Blair Jordan Acquires 160,000 Shares of Common Stock
SEC Form 4 Filing
Blair Jordan, CEO of 180 Life Sciences Corp., reports acquiring 160,000 shares of common stock on February 20, 2025.
Summary
- On February 20, 2025, Blair Jordan, the CEO of 180 Life Sciences Corp., acquired 160,000 shares of common stock.
- These shares were issued in consideration for services rendered and to be rendered to the Issuer as an officer of the Issuer under the company's 2022 Equity Compensation Plan.
- The reporting person may be deemed to beneficially own 43,166 shares of common stock held by Dr. Woody due to an irrevocable voting proxy.
- These shares are subject to a Voting Agreement where Dr. Woody agreed to vote a total of 43,166 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to February 5, 2026, the date after August 5, 2025, that Dr. Woody has sold all of the shares or the date that the Issuer terminates the Voting Agreement.
- The acquired shares are restricted stock that vest in two equal installments on January 1, 2026, and December 31, 2026, contingent upon continued service to the Issuer.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The CEO acquiring shares is generally a good sign, indicating confidence in the company. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's prospects.
Positives
- The acquisition of shares by the CEO demonstrates confidence in the company's future.
- The vesting schedule incentivizes continued service and commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the restricted stock.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of company executives.
Stakeholder Impact
- The stock acquisition by the CEO could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of Voting Agreement between the Issuer, Blair Jordan, and Dr. James Woody. |
| 02/20/2025 | Date of transaction: Blair Jordan acquired 160,000 shares of common stock. |
| 02/21/2025 | Date of Form 4 signature. |
| 08/05/2025 | Date after which the Voting Agreement may terminate if Dr. Woody has sold all shares. |
| 01/01/2026 | First vesting date for 1/2 of the restricted stock shares. |
| 02/05/2026 | Termination date of the Voting Agreement. |
| 12/31/2026 | Second vesting date for the remaining 1/2 of the restricted stock shares. |
Keywords
180 Life Sciences Corp., Blair Jordan, stock acquisition, CEO, beneficial ownership, Form 4, ATNF, voting agreement, restricted stock, equity compensation plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.